UroGen Pharma Ltd.
URGN
$9.66
-$0.01-0.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 4.40% | 20.87% | 3.35% | 9.24% | 30.06% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.40% | 20.87% | 3.35% | 9.24% | 30.06% |
| Cost of Revenue | 8.09% | 3.63% | -8.76% | -23.71% | 1.02% |
| Gross Profit | 4.00% | 23.08% | 4.94% | 14.24% | 34.21% |
| SG&A Expenses | 37.50% | 33.03% | 33.62% | 11.54% | 13.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.04% | 24.44% | 30.57% | 13.47% | -0.61% |
| Operating Income | -81.79% | -29.96% | -67.98% | -16.76% | 27.97% |
| Income Before Tax | -57.31% | -7.74% | -38.55% | -6.76% | 21.36% |
| Income Tax Expenses | -31.27% | 1,111.11% | -29.63% | 157.14% | 459.36% |
| Earnings from Continuing Operations | -44.19% | -8.20% | -38.39% | -6.86% | 9.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.19% | -8.20% | -38.39% | -6.86% | 9.88% |
| EBIT | -81.79% | -29.96% | -67.98% | -16.76% | 27.97% |
| EBITDA | -83.72% | -31.27% | -69.83% | -17.36% | 28.07% |
| EPS Basic | -10.84% | 18.91% | 11.82% | 25.47% | 42.45% |
| Normalized Basic EPS | -17.12% | 19.26% | 11.72% | 25.55% | 49.78% |
| EPS Diluted | -10.84% | 18.91% | 11.82% | 25.47% | 42.45% |
| Normalized Diluted EPS | -17.12% | 19.26% | 11.72% | 25.55% | 49.78% |
| Average Basic Shares Outstanding | 30.09% | 33.44% | 56.94% | 43.38% | 56.58% |
| Average Diluted Shares Outstanding | 30.09% | 33.44% | 56.94% | 43.38% | 56.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |